Back

Bailout inclisiran-based triple lipid-lowering therapy reduces plaque lipid content in stable coronary artery disease patients

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Pharmacology in coronary artery disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Karlis Trusinskis

Paul Stradins Clinical University Hospital, Riga (Latvia)

6 More presentations in this session

Presentation thumbnail
Optimal antiplatelet therapy for patients after antiplatelet therapy-induced gastrointestinal bleeding: when to resume?
Professor R. Huang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
A meta-analysis on the efficacy of ticagrelor monotherapy after 3 months of dual antiplatelet therapy vs ticagrelor plus aspirin dual therapy on patients with ACS who underwent PCI
Doctor L. Galera (Manila, PH)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of under-dose non-vitamin K antagonist oral anticoagulant with atrial fibrillation undergoing PCI: Insights from a nationwide population-based cohort study
Ms G. Youk (Busan, KR)
Abstract Slides Video
Presentation thumbnail
Interplay among proton pump inhibitors, platelet reactivity and CYP2C19 genotyping in clopidogrel-treated patients after drug-eluting stent implantation
Assistant Professor J. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Effectiveness and tolerability of trimetazidine 80mg once daily in patients with chronic coronary syndrome: the V-GOOD observational study
Professor L. Wolff Gowdak (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacology in coronary artery disease

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Inclisiran-containing low-density lipoprotein cholesterol reduction effectively stabilizes atherosclerotic plaques
thumbnail
Congress Presentation
Intensified hypolipidaemic therapy with inclisiran for atherosclerotic plaque stabilization
thumbnail
Congress Presentation
Association between high-intensity lipid-lowering therapy and atherosclerotic plaque content changes assed by iMAP-IVUS and near-infrared spectroscopy in patients with premature atherosclerosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources